ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.
Shilpa Biologicals has entered a co‑development and supply agreement with Finland's Orion for a nivolumab biosimilar. The partnership expands Shilpa's European market footprint.
Shilpa Medicare's Bengaluru facility concluded a USFDA inspection with five procedural observations. The company expects no material impact on operations and will respond within timelines.